Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 23, 2026 07:17 ET | Source: VALNEVA

Pfizer et Valneva annoncent que le candidat vaccin contre la maladie de Lyme démontre une forte efficacité dans l’essai de Phase 3 VALOR

Le candidat vaccin PF-07307405 (LB6V) a démontré une efficacité de plus de 70 % dans la prévention de la maladie de Lyme chez les personnes âgées de cinq ans et plus.Le candidat vaccin a été bien...
March 23, 2026 07:05 ET | Source: Kraig Biocraft Laboratories

Kraig Biocraft Laboratories Increases R&D Capacity, as Project Atlas Breakthroughs Creating New Spider Silk Transgenics

Kraig Labs (OTCQB: KBLB) significantly expanded its R&D capacity to keep pace with rapid progress of its Project Atlas advanced materials initiative
March 23, 2026 07:02 ET | Source: Ocugen

Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced...
March 23, 2026 07:00 ET | Source: Avalo Therapeutics

Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates

Topline data expected from Phase 2 LOTUS trial of abdakibart (AVTX-009) for the treatment of hidradenitis suppurativa in the second quarter of 2026Cash, cash equivalents and short-term investments of...
March 23, 2026 07:00 ET | Source: Tessera Therapeutics

Tessera Therapeutics Receives Grant to Advance In Vivo Gene Writing Approaches Towards a Potential Human Immunodeficiency Virus (HIV) Cure

SOMERVILLE, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- SOMERVILLE, Mass., March 23, 2026 /GLOBE NEWSWIRE/ Tessera Therapeutics (“Tessera”), the biotechnology company pioneering a new approach in...
March 23, 2026 06:30 ET | Source: Apogee Therapeutics

Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis

APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, including:- 75% and 85% patients maintained EASI-75- 86% and 78% patients...
March 23, 2026 04:12 ET | Source: Bavarian Nordic A/S

Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprogram

KØBENHAVN, Danmark, 23. marts 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggør transaktioner under aktietilbagekøbsprogrammet, der blev iværksat den 12. marts 2026, hvorunder selskabet vil...
March 23, 2026 04:12 ET | Source: Bavarian Nordic A/S

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

COPENHAGEN, Denmark, March 23, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares...
March 23, 2026 03:00 ET | Source: Amphista Therapeutics

Amphista Therapeutics announces three presentations at the American Association for Cancer Research Annual Meeting on its next-generation Targeted Glue™ degrader programs

Cambridge, UK, 23rd March 2026 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue™ degraders, today announces three...
March 23, 2026 03:00 ET | Source: Draupnir Bio

Groundbreaking Danish research project launches to cure Parkinson’s disease

A new research project aims to develop the world’s first therapy to eliminate and prevent the spread of a toxic brain protein that drives Parkinson’s disease. Innovation Fund Denmark has invested DKK...